Skip to content
drillr.ai
Sign up

PSNL

Personalis, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$15.82
−0.66%
Ask drillr

  • Oct 26, 2026, 09:46 UTC

    Bleichmar Fonti & Auld LLP announced that it is investigating Personalis's going-private merger with Tempus AI at $16.25 per share.

    Source:

  • Oct 21, 2026, 18:45 UTC

    BFA Law announced an investigation into Personalis following a merger deal announced at $16.25 per share.

    Source:

  • Oct 21, 2026, 10:00 UTC

    Personalis announced that two oral and two poster presentations featuring its NeXT Personal ctDNA test are scheduled for the ESMO Congress 2026.

    Source:

  • Oct 20, 2026, 10:00 UTC

    Personalis announced the commercial launch of optional Real-Time Variant Tracker supplemental results in its NeXT Personal MRD test report, identifying clinically relevant resistance and therapeutically targetable variants over time.

    Source:

  • Aug 4, 2026, 22:16 UTC

    Personalis reported a Q2 2026 net loss of $0.30 per share, missing the Zacks Consensus Estimate of a $0.25 loss and wider than the $0.23 loss a year earlier.

    Source:

  • Aug 4, 2026, 18:04 UTC

    Wohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.

    Source:

  • Jul 20, 2026, 12:31 UTC

    TEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.

    Source:

  • Jul 14, 2026, 10:00 UTC

    Personalis, Inc. announced it has received UKCA marking for its NeXT Personal Dx test, enabling clinical use in Great Britain.

    Source:

  • Jun 9, 2026, 10:00 UTC

    Personalis obtained CE-IVD marking for its EDTA Blood Collection Kit and cfDNA Blood Collection Kit under the EU IVDR regulation.

    Source: